Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Orelabrutinib in Mild to Moderate SLE
NCT04305197Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Jul 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in systemic lupus erythematosus (SLE), sponsored by InnoCare Pharma. Started Jul 2020; status: completed.
02
Drugs
orelabrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04305197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305197.